SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The S&P 500 is experiencing heightened volatility and a sharp reversal following a televised address by President Trump, which signaled a prolonged military operation in Iran and dashed investor hopes for an immediate ceasefire. Community discussion is dominated by concerns over escalating energy costs, frustration with the administration's inconsistent messaging, and widespread skepticism regarding the market's stability heading into the upcoming long weekend.

Invesco QQQ Trust Series 1 - Units of beneficial interest

Invesco QQQ Trust (QQQ) is seeing intense trading activity as investors react to the potential for further military escalation in the Middle East following upcoming government remarks. The community is sharply divided, with traders debating whether market price action reflects a genuine de-escalation of conflict or a temporary bull trap driven by misinformation, leading many to adopt a defensive, cash-heavy stance ahead of the holiday weekend.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and the online community closely monitor a highly anticipated prime-time address regarding the ongoing conflict in Iran. The stock is facing intense volatility and polarizing debate as the community actively discusses the potential market impact of the president's military strategy, geopolitical uncertainty, and broader skepticism surrounding the company's long-term operational viability.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as investors await imminent Q1 delivery reports and monitor geopolitical developments involving the Strait of Hormuz. The community remains deeply divided between bullish sentiment regarding long-term resilience and AI initiatives, and bearish concerns over slowing demand and competitive pressures.

Spdr Dow Jones Industrial Average ETF Trust - Units of undivided interest in DIAMONDS Trust Series 1

The SPDR Dow Jones Industrial Average ETF (DIA) is experiencing significant volatility and downward pressure as the market reacts to escalating geopolitical tensions in the Middle East and concerns over energy inflation. Community discussions are highly polarized, with traders debating the impact of potential ground operations, conflicting reports regarding diplomatic negotiations, and widespread frustration over the unpredictability of leadership rhetoric.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing high volatility as investors remain divided over the company's aggressive Bitcoin acquisition strategy and ongoing share dilution. Market participants are intensely debating whether the stock serves as a strategic leverage play on digital assets or if its reliance on debt and equity offerings poses a structural risk to long-term shareholders.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is currently at the center of a volatile market debate as investors weigh its role as an AI infrastructure leader against broader geopolitical risks and fluctuating demand for semiconductor supply chains. The community remains sharply divided, with bulls pointing to the company's long-term dominance in compute and data center partnerships, while short-term traders closely monitor technical resistance levels and news-driven market swings.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is currently facing intense market volatility as traders react to shifting geopolitical narratives following high-stakes political rhetoric and uncertainty surrounding military operations in the Middle East. The community remains deeply divided, with bulls pointing to long-term institutional accumulation and potential legislative progress, while bears highlight technical vulnerabilities and the impact of broader economic instability on risk assets.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is seeing high engagement as investors react to a confirmed launch window for its BlueBird-7 satellite, while simultaneously navigating broader market volatility linked to international geopolitical tensions. Community sentiment is deeply polarized, with many users debating the company's execution timeline against its long-term potential in the direct-to-cell satellite market.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as investors scrutinize its AI strategy and recent leadership hires against a backdrop of broader market volatility and geopolitical concerns in the Middle East. The community remains deeply divided, with discussions ranging from intense political debates over the impact of government policy on market performance to technical analysis regarding the stock's recent relative weakness compared to its peers.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The investigational therapy was granted Rare Pediatric Disease designation for the treatment of DMD in December and an Orphan Drug Designation in January.&nbsp;</li><li>The company reported net loss per share of $4.04 for 2025, compared to a loss of $3.04 in 2024, and above an analyst estimate of a loss of $3.91.</li><li>Last month, Atossa said that the company will not proceed with advancing its drug in metastatic breast cancer.</li></ul>Shares of Atossa Therapeutics (ATOS) slipped 4% after hours on Wednesday after the company said that it continues to align its resources towards potential commercialization of (Z)-endoxifen after it reported a wider full year loss.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.atossatherapeutics.com/2026-03-25-Atossa-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2025-Financial-Results-and-Provides-a-Corporate-Update">said</a> that it is working to advance its experimental drug (Z)-endoxifen in certain rare disease indications such as Duchenne Muscular Dystrophy (DMD) and McCune-Albright Syndrome (MAS) in addition to breast cancer. The investigational therapy was granted Rare Pediatric Disease designation for the treatment of DMD in December and an Orphan Drug Designation in January.“We believe these FDA designations are important for future development as they both help to speed the FDA review process as well as provide potential financial benefits in the future," CEO Steven Quay said on Wednesday.Last month, Atossa said that the company will not proceed with advancing its drug in metastatic breast cancer due to the overall cost and timeline required to conduct later-stage studies in the indication. The company then said it will prioritize its resources on other oncology and rare disease areas with “higher potential returns on investments.”<h2 class="st-heading-2">Q4 Earnings</h2>The company said on Wednesday that its operating expenses rose in 2025 to $37.1 million, compared to $9.5 million in 2024, owing to a significant rise in research and development expenses for (Z)-endoxifen.The company reported net loss per share of $4.04 for 2025, compared to a loss of $3.04 in 2024, and above an analyst estimate of a loss of $3.91. The company ended the year with cash and cash equivalents of $41.29 million, compared to $71.08 million as of 2024-end.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ATOS stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<a href="https://stocktwits.com/symbol/ATOS">ATOS stock</a> has dropped 50% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/wkhs-stock-rallies-after-hours-on-unveiling-cheaper-electric-delivery-van/cZ3pPW4RIjI">WKHS Stock Rallies After Hours On Unveiling Cheaper Electric Delivery Van</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Atossa Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug

The company said that it is working to advance its experimental drug (Z)-endoxifen in certain rare disease indications such as Duchenne Muscular Dystrophy (DMD) and McCune-Albright Syndrome (MAS) in addition to breast cancer.

Equity

The company said that it is working to advance its experimental drug (Z)-endoxifen in certain rare disease indications such as Duchenne Muscular Dystrophy (DMD) and McCune-Albright Syndrome (MAS) in addition to breast cancer.


Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update

Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and...

Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives

Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two...

Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference

Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference Atossa Therapeutics Presents Clinical Trial Update Highlighting...

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026...

Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program

Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program Atossa Therapeutics Maintains Strong...

Atossa Genetics (NASDAQ:ATOS) Sees Large Volume Increase - What's Next?

Atossa Genetics (NASDAQ:ATOS) Sees Large Volume Increase - Still a Buy...

<ul class="summary-bullets"><li>Each of 15 shares of the company’s common stock outstanding was combined into one new share of common stock.</li><li>No fractional shares were issued as a result of the split.&nbsp;</li><li>In January, the FDA granted Orphan Drug Designation to Atossa’s (Z)-endoxifen for the treatment of Duchenne muscular dystrophy.</li></ul>Shares of Atossa Therapeutics Inc. (ATOS) fell a steep 32% on Monday after the stock began trading on a split adjusted basis at trade open.Atossa <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001488039/000119312526021727/atos-20260120.htm">said</a> last week that its Board of Directors has approved a reverse stock split of the company’s common stock, at a ratio of 15:1, with an effective time of 12:01 a.m. Eastern Time on February 2, 2026.Each of 15 shares of the company’s common stock outstanding was combined into one new share that started trading on a split-adjusted basis on Monday. No fractional shares were issued as a result of the split.<h2 class="st-heading-2">New Designations</h2>In January, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Atossa’s (Z)-endoxifen for the treatment of Duchenne muscular dystrophy. The drug was previously granted Rare Pediatric Disease designation for the treatment of DMD as well.Duchenne muscular dystrophy is a severe, progressive, X-linked genetic disorder, primarily affecting boys, characterized by the lack of the protein dystrophin, leading to muscle degeneration.The orphan drug designation is granted to therapies intended to treat rare diseases and offers incentives such as regulatory support. The drug is yet to be approved for any indication. However, the FDA gave clearances for studying the drug in metastatic breast cancer earlier in January.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ATOS stock stayed within the ‘bullish’ territory, while message volume remained at ‘high’ levels.A Stocktwits user highlighted concerns about a potential dilution. The company has cash and cash equivalents of $51.8 million as of September end. &nbsp;<stembedurl>https://www.stocktwits.com/St0ckt0k101/message/643702353</stembedurl>Another said that they are “relieved” the company didn’t get delisted.<stembedurl>https://www.stocktwits.com/RealTurd/message/643701100</stembedurl><a href="https://stocktwits.com/symbol/ATOS">ATOS stock</a> has lost 54% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-seemingly-confirms-xai-spacex-merger-talks/cZbgtmrR4kZ">Elon Musk Seemingly Confirms xAI-SpaceX Merger Talks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ATOS Stock Tumbles 32% — Here’s What Retail Investors Think Of The Reverse Stock Split

Atossa Therapeutics said last week that its board has approved a reverse stock split of the company’s common stock, at a ratio of 15:1, with an effective time of 12:01 a.m. Eastern Time on February 2, 2026. 

Atossa Genetics Inc. (NASDAQ:ATOS) Short Interest Up 56.4% in January

Atossa Genetics Inc. (NASDAQ:ATOS - Get Free Report) was the recipient of a large increase in short interest in the month of January. As of January 15th, there was short interest totaling 3,621,023...

Atossa Genetics (NASDAQ:ATOS) Shares Set to Reverse Split on Monday, February 2nd

Atossa Genetics Inc. (NASDAQ:ATOS - Free Report) shares are going to reverse split on the morning of Monday, February 2nd. The 1-15 reverse split was announced on Monday, January 26th. The number of...

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Atossa Therapeutics Inc

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.92	--	--	N/A
Q4 '25	-$1.14	-$1.19	-4.62%	MISSED
Q3 '25	-$0.06	-$1.05	-1515.38%	MISSED
Q2 '25	-$0.06	-$0.07	-21.74%	MISSED
Q1 '25	-$0.06	-$0.05	11.77%	BEAT

ATOS
Atossa Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest ATOS News

ATOSAtossa Therapeutics Inc